Cargando…
PB2060: THE MDS-SPECIFIC COMORBIDITY INDEX (MDS-CI) PREDICTS SURVIVAL INDEPENDENTLY FROM DIPSS AND MIPSS70 IN PATIENTS WITH OVERT MYELOFIBROSIS NOT ELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION.
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431484/ http://dx.doi.org/10.1097/01.HS9.0000851072.40949.cf |
| _version_ | 1784780068456759296 |
|---|---|
| author | Koster, K.-L. Messerich, N.-M. Volken, T. Cogliatti, S. Lehmann, T. Holbro, A. Benz, R. Graf, L. Demmer, I. Jochum, W. Silzle, T. |
| author_facet | Koster, K.-L. Messerich, N.-M. Volken, T. Cogliatti, S. Lehmann, T. Holbro, A. Benz, R. Graf, L. Demmer, I. Jochum, W. Silzle, T. |
| author_sort | Koster, K.-L. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9431484 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94314842022-08-31 PB2060: THE MDS-SPECIFIC COMORBIDITY INDEX (MDS-CI) PREDICTS SURVIVAL INDEPENDENTLY FROM DIPSS AND MIPSS70 IN PATIENTS WITH OVERT MYELOFIBROSIS NOT ELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION. Koster, K.-L. Messerich, N.-M. Volken, T. Cogliatti, S. Lehmann, T. Holbro, A. Benz, R. Graf, L. Demmer, I. Jochum, W. Silzle, T. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431484/ http://dx.doi.org/10.1097/01.HS9.0000851072.40949.cf Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Koster, K.-L. Messerich, N.-M. Volken, T. Cogliatti, S. Lehmann, T. Holbro, A. Benz, R. Graf, L. Demmer, I. Jochum, W. Silzle, T. PB2060: THE MDS-SPECIFIC COMORBIDITY INDEX (MDS-CI) PREDICTS SURVIVAL INDEPENDENTLY FROM DIPSS AND MIPSS70 IN PATIENTS WITH OVERT MYELOFIBROSIS NOT ELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION. |
| title | PB2060: THE MDS-SPECIFIC COMORBIDITY INDEX (MDS-CI) PREDICTS SURVIVAL INDEPENDENTLY FROM DIPSS AND MIPSS70 IN PATIENTS WITH OVERT MYELOFIBROSIS NOT ELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION. |
| title_full | PB2060: THE MDS-SPECIFIC COMORBIDITY INDEX (MDS-CI) PREDICTS SURVIVAL INDEPENDENTLY FROM DIPSS AND MIPSS70 IN PATIENTS WITH OVERT MYELOFIBROSIS NOT ELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION. |
| title_fullStr | PB2060: THE MDS-SPECIFIC COMORBIDITY INDEX (MDS-CI) PREDICTS SURVIVAL INDEPENDENTLY FROM DIPSS AND MIPSS70 IN PATIENTS WITH OVERT MYELOFIBROSIS NOT ELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION. |
| title_full_unstemmed | PB2060: THE MDS-SPECIFIC COMORBIDITY INDEX (MDS-CI) PREDICTS SURVIVAL INDEPENDENTLY FROM DIPSS AND MIPSS70 IN PATIENTS WITH OVERT MYELOFIBROSIS NOT ELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION. |
| title_short | PB2060: THE MDS-SPECIFIC COMORBIDITY INDEX (MDS-CI) PREDICTS SURVIVAL INDEPENDENTLY FROM DIPSS AND MIPSS70 IN PATIENTS WITH OVERT MYELOFIBROSIS NOT ELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION. |
| title_sort | pb2060: the mds-specific comorbidity index (mds-ci) predicts survival independently from dipss and mipss70 in patients with overt myelofibrosis not eligible for allogeneic stem cell transplantation. |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431484/ http://dx.doi.org/10.1097/01.HS9.0000851072.40949.cf |
| work_keys_str_mv | AT kosterkl pb2060themdsspecificcomorbidityindexmdscipredictssurvivalindependentlyfromdipssandmipss70inpatientswithovertmyelofibrosisnoteligibleforallogeneicstemcelltransplantation AT messerichnm pb2060themdsspecificcomorbidityindexmdscipredictssurvivalindependentlyfromdipssandmipss70inpatientswithovertmyelofibrosisnoteligibleforallogeneicstemcelltransplantation AT volkent pb2060themdsspecificcomorbidityindexmdscipredictssurvivalindependentlyfromdipssandmipss70inpatientswithovertmyelofibrosisnoteligibleforallogeneicstemcelltransplantation AT cogliattis pb2060themdsspecificcomorbidityindexmdscipredictssurvivalindependentlyfromdipssandmipss70inpatientswithovertmyelofibrosisnoteligibleforallogeneicstemcelltransplantation AT lehmannt pb2060themdsspecificcomorbidityindexmdscipredictssurvivalindependentlyfromdipssandmipss70inpatientswithovertmyelofibrosisnoteligibleforallogeneicstemcelltransplantation AT holbroa pb2060themdsspecificcomorbidityindexmdscipredictssurvivalindependentlyfromdipssandmipss70inpatientswithovertmyelofibrosisnoteligibleforallogeneicstemcelltransplantation AT benzr pb2060themdsspecificcomorbidityindexmdscipredictssurvivalindependentlyfromdipssandmipss70inpatientswithovertmyelofibrosisnoteligibleforallogeneicstemcelltransplantation AT grafl pb2060themdsspecificcomorbidityindexmdscipredictssurvivalindependentlyfromdipssandmipss70inpatientswithovertmyelofibrosisnoteligibleforallogeneicstemcelltransplantation AT demmeri pb2060themdsspecificcomorbidityindexmdscipredictssurvivalindependentlyfromdipssandmipss70inpatientswithovertmyelofibrosisnoteligibleforallogeneicstemcelltransplantation AT jochumw pb2060themdsspecificcomorbidityindexmdscipredictssurvivalindependentlyfromdipssandmipss70inpatientswithovertmyelofibrosisnoteligibleforallogeneicstemcelltransplantation AT silzlet pb2060themdsspecificcomorbidityindexmdscipredictssurvivalindependentlyfromdipssandmipss70inpatientswithovertmyelofibrosisnoteligibleforallogeneicstemcelltransplantation |